3 takeaways from a European obesity scientific meeting

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 01 Oct, 16:16 UTC

Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

science

Sources

• T23 takeaways from a European obesity scientific meetingBioPharma Dive / Healthcare Dive / MedTech Dive01 Oct, 16:16